z-logo
open-access-imgOpen Access
Oral immunogenicity of porcine reproductive and respiratory syndrome virus antigen expressed in transgenic banana
Author(s) -
Chan HuiTing,
Chia MinYuan,
Pang Victor Fei,
Jeng ChianRen,
Do YiYin,
Huang PungLing
Publication year - 2013
Publication title -
plant biotechnology journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.525
H-Index - 115
eISSN - 1467-7652
pISSN - 1467-7644
DOI - 10.1111/pbi.12015
Subject(s) - biology , porcine reproductive and respiratory syndrome virus , immunogenicity , recombinant dna , virology , heterologous , transgene , virus , antigen , microbiology and biotechnology , gene , immunology , biochemistry
Summary Porcine reproductive and respiratory syndrome virus ( PRRSV ) is a persistent threat of economically significant influence to the swine industry worldwide. Recombinant DNA technology coupled with tissue culture technology is a viable alternative for the inexpensive production of heterologous proteins in planta . Embryogenic cells of banana cv. ‘Pei chiao’ ( AAA ) have been transformed with the ORF 5 gene of PRRSV envelope glycoprotein ( GP 5) using Agrobacterium ‐mediated transformation and have been confirmed. Recombinant GP 5 protein levels in the transgenic banana leaves were detected and ranged from 0.021%–0.037% of total soluble protein. Pigs were immunized with recombinant GP 5 protein by orally feeding transgenic banana leaves for three consecutive doses at a 2‐week interval and challenged with PRRSV at 7 weeks postinitial immunization. A vaccination‐dependent gradational increase in the elicitation of serum and saliva anti‐ PRRSV IgG and IgA was observed. Furthermore, significantly lower viraemia and tissue viral load were recorded when compared with the pigs fed with untransformed banana leaves. The results suggest that transgenic banana leaves expressing recombinant GP 5 protein can be an effective strategy for oral delivery of recombinant subunit vaccines in pigs and can open new avenues for the production of vaccines against PRRSV .

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here